Akari Therapeutics (NASDAQ:AKTX – Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($688.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($686.67), reports.
Akari Therapeutics Stock Up 255.4%
AKTX traded up $13.13 during midday trading on Friday, hitting $18.27. The stock had a trading volume of 32,951,741 shares, compared to its average volume of 417,685. Akari Therapeutics has a 1 year low of $3.02 and a 1 year high of $56.80. The business has a fifty day moving average of $5.37 and a 200 day moving average of $10.53.
Institutional Investors Weigh In On Akari Therapeutics
A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC bought a new position in Akari Therapeutics PLC (NASDAQ:AKTX – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned 5.95% of Akari Therapeutics as of its most recent SEC filing. 5.06% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on AKTX
Key Akari Therapeutics News
Here are the key news stories impacting Akari Therapeutics this week:
- Positive Sentiment: Akari reported breakthrough preclinical data showing AKTX-101 worked synergistically with KRAS inhibition in pancreatic cancer models, boosting investor optimism about its lead ADC program. Article Title
- Positive Sentiment: Market commentary highlighted the stock’s surge after the cancer-data release, with some traders pointing to possible upside if the platform continues to show promise. Article Title
- Neutral Sentiment: Akari announced a $5.5 million private placement offering to fund development of AKTX-101, providing near-term cash but also signaling dilution risk. Article Title
- Neutral Sentiment: The company also announced an ADS ratio change and reverse split, a corporate action that can alter the share structure and often contributes to trading volatility. Article Title
- Negative Sentiment: Akari’s latest quarterly results missed expectations by a wide margin, underscoring that the company remains highly speculative and financially challenged. Article Title
- Negative Sentiment: Trading in AKTX was halted multiple times for LULD pauses, reflecting extreme intraday volatility as investors reacted to the news flow. Article Title
Akari Therapeutics Company Profile
Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.
Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.
Featured Stories
- Five stocks we like better than Akari Therapeutics
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
